Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.O)

SUPN.O on Consolidated Issue listed on NASDAQ Global Market

24.73USD
30 Sep 2016
Change (% chg)

$0.10 (+0.41%)
Prev Close
$24.63
Open
$24.73
Day's High
$25.08
Day's Low
$24.50
Volume
436,737
Avg. Vol
575,141
52-wk High
$26.84
52-wk Low
$9.51

SUPN.O

Chart for SUPN.O

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi... (more)

Overall

Beta: 1.72
Market Cap(Mil.): $1,219.39
Shares Outstanding(Mil.): 49.51
Dividend: --
Yield (%): --

Financials

  SUPN.O Industry Sector
P/E (TTM): 48.29 36.90 36.83
EPS (TTM): 0.51 -- --
ROI: 19.27 14.48 13.93
ROE: 21.45 15.27 14.84

BRIEF-Supernus Pharma receives FDA tentative approval for expanded label of Trokendi XR

* Supernus receives FDA tentative approval for expanded label of Trokendi XR to include migraine prophylaxis in adults

Aug 19 2016

BRIEF-Supernus Pharma says Charles W Newhall III elected chairman

* Supernus announces resignation of Dr. James Barrett from board of directors; Charles W. Newhall, III elected chairman Source text for Eikon: Further company coverage:

Aug 12 2016

BRIEF-Supernus Pharmaceuticals CEO Jack Khattar joins scPharmaceuticals board

* Supernus Pharmaceuticals founder and CEO Jack Khattar joins scPharmaceuticals board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 12 2016

BRIEF-Supernus reiterates guidance

* Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine

Jun 16 2016

BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xr

* Supernus enters into partial settlement agreement with Actavis on oxtellar xr

May 10 2016

BRIEF-Supernus Pharmaceuticals Q1 earnings per share $0.08

* Q1 earnings per share view $0.09 -- Thomson Reuters I/B/E/S

May 03 2016

BRIEF-Supernus Pharmaceuticals CEO 2015 total compensation $3.2 mln

* CEO Jack A. Khattar's 2015 total compensation was $3.2 million versus $1.7 million in 2014 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 19 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $42.29 +0.85
AstraZeneca plc (AZN.L) 5,004.00p -22.00
Eli Lilly and Co (LLY.N) $80.26 +0.52
Shire PLC (SHP.L) 4,998.00p -63.00
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,464.00p +4.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Jefferson Research
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.